| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 969.30 | 4.3% | 25.4% |
| Total Income | 977.36 | 4.0% | 24.9% |
| Expenditure | 821.12 | 4.1% | 24.0% |
| PBT | 156.24 | 3.9% | 29.5% |
| Net Profit | 116.06 | 0.8% | 29.7% |
| OPM | 18.37% | 0.17pp | 0.46pp |
| NPM | 11.88% | 0.38pp | 0.45pp |
| EPS | 15.43 | 0.8% | 29.8% |
Record growth masks sequential profit fade and rising cost pressure
Q2 revenue jumped 25.4% YoY and profit 29.7%, corroborating the upswing narrative. But quarter-on-quarter, revenue growth slowed to 2.8% and profit actually fell 3.0%—a signal that cost inflation is outpacing pricing power. The real test begins now.
25.4%
₹969.3 Cr
29.9%
₹116.1 Cr
2.8%
Management claimed 4.3%
-3.0%
Q1 ₹119.4 Cr vs Q2 ₹116.1 Cr
The headline reads like a blowout: Timken posted its best YoY growth in years, +25.4% revenue and +29.7% profit, tracking management's bullish narrative on exports, industrial segment accretion, and capacity expansion. On the surface, it works. But the real tension sits in the quarter-on-quarter numbers. Despite a 2.8% sequential revenue bump—short of management's stated 4.3%—profit actually declined 3.0%. That reversal, with input costs rising across carbides (up 200%), steel, and gas, signals one hard truth: margin expansion has hit a wall.
The margin squeeze: YoY masks QoQ decay
Operating profit margin improved 50 basis points YoY to 18.4%, but the quarterly trajectory tells a different story. Q1 FY27 must have posted a higher OPM to yield H1 OPM below Q2's 18.4%. More important, the MD on the call was candid: "Cost is going up and will still go up…nobody can absorb it. Industry cannot absorb it." Yet customer pass-through remains vague. The company is "working on it continuously," but the timing and magnitude are unknown. Meanwhile, QoQ profit declined despite revenue growth—a textbook sign that price increases are not yet flowing through, or that unfavourable mix (rail weakness at just 16% of revenue) is dampening realized pricing.
Management's claims vs. what holds up
Strong double-digit revenue and profit growth
+25.4% revenue, +29.7% PAT YoY
Supported
4.3% revenue growth over Q1
Actual QoQ revenue 2.8%
Overstated (50% miss)
Bharuch targeting 70% spherical roller bearing utilization by Aug-Sep
Bharuch at 60% SRB utilization as of Q2 call; target deferred to year-end
Missed / Slipped ~3 months
Exports grew 60% YoY, driving segment momentum
Q2 exports ₹262.7 Cr (27% of total), +60% YoY confirmed in Q&A
Supported
Rail segment recovering; tenders in full swing; 2–3 weeks to orders
Rail only ₹156.7 Cr (16% of Q2), down-mix. Trial runs Nov–Dec; PPAPs after.
Partial (recovery delayed to Q3–Q4)
Industry must absorb cost inflation; we will pass it through
QoQ PAT -3% despite +2.8% revenue growth
Unproven (pass-through not yet visible in realized margins)
What changed on this call
Timken's Q1 narrative was cautiously bullish on capacity expansion and exports. Q2 elevated three new headwinds into primary risk territory:
Cost inflation as structural near-term risk (not transient)
Bharuch utilization target slipped from Aug–Sep to year-end (3-month delay)
Rail segment weakness now explicitly flagged (16% of mix, tenders delayed)
Exports & industrial segment revealed as stand-out strength (+60% YoY exports, margin-accretive mix)
Capex guidance reaffirmed but not upgraded (8–10% of revenue; no multi-year growth acceleration target)
The bull-bear ledger
Revenue +25.4% YoY, profit +29.7% YoY (momentum corroborated)
Exports +60% YoY, 27% of revenue and accelerating (diversification away from auto, higher margin)
Industrial segment (SRB, CRB) margin-accretive; offsetting auto weakness
Bharuch ramp progressing (₹75 Cr Q2 vs ₹50 Cr Q1, +50% QoQ); capex pipeline real (rail ₹120 Cr, Bharuch ₹70 Cr, GGB ₹35–70 Cr)
QoQ PAT declined 3.0% despite 2.8% revenue growth (margin compression underway)
Cost headwinds "will still go up"; customer pass-through timing and magnitude unproven
Rail segment (16% of mix) delayed; recovery hinges on Nov–Dec trial runs and tender conversion
Bharuch at 60%, below 70% Aug–Sep target; customer MOC delays may persist
Capex execution risk across three fronts (Bharuch, rail, GGB); asset turn expectations untested
Export concentration: 27% of revenue, heavily North American rail & process industries; customer concentration unquantified
How the street is positioned
Timken trades at ₹3,020, down 37.3% from its all-time high of ₹4,817.9, but up 12.4% off its 52-week low. The stock sits above its 20-day moving average (₹2,907) but below both the 50-day (₹3,062) and 200-day (₹3,269), signalling a recovery attempt within a longer downtrend. RSI is neutral at 56.4—neither overbought nor oversold.
The ownership story is more telling. Foreign institutional investors have exited steadily: FII ownership fell from 9.44% in FY26 Q1 to 7.32% as of FY27 Q1, a loss of 212 basis points. In the same period, domestic institutions held steady around 30%, and promoters remained locked at 51.05%. No insider buying near the lows—a yellow flag. The FII exodus is the market's own verdict: even as Timken posts record YoY growth, institutions are trimming, likely spooked by the sequential margin decay and cost headwinds visible to any analyst reading the Q&A.
In short, the stock's 37% drawdown reflects the street's awareness that headline growth masks softening momentum. The FII exit confirms it. This is not a recovery play; it is a "prove the pricing power" play.
Risks, ranked by how much they should concern a holder
Margin compression from unabsorbed cost inflation
HIGHCarbides +200%, steel and gas rising. QoQ PAT already -3% despite revenue growth. MD acknowledged "industry cannot absorb it," yet pass-through timing and magnitude are unknown. If Q3 PAT continues to decline YoY while revenue grows, the cycle turns bear.
Bharuch utilization shortfall and capex ROI uncertainty
HIGHBharuch at 60% vs 70% target (Aug–Sep missed, deferred to year-end). ₹70 Cr capex underway; asset turn expectation (1–1.5x) untested. MOC delays on customer side may persist. If utilization stalls below 65%, payoff extends further and ROI disappoints.
Rail tenders conversion risk and segment mix headwind
MEDIUM-HIGHRail only 16% of Q2 revenue, weighed by delayed tenders. Trial runs Nov–Dec; PPAPs after. If orders don't materialize as expected, or convert at lower volumes, Q3–Q4 earnings will miss. Rail is a margin-accretive segment; weakness is a drag.
Capex execution across three fronts (INR 225+ Cr over 2 years)
MEDIUMBharuch ₹70 Cr, rail ₹120 Cr, GGB ₹35–70 Cr. Asset turns, payoff timelines, and synergies are untested. Execution delays or capex overruns would compress FY27–28 free cash flow and extend payback.
Export concentration and customer dependence
MEDIUMExports 27% of Q2 revenue, +60% YoY. Heavily weighted to North American rail and process industries (ZF, Flenders gearbox references). No customer concentration disclosed. A loss of a major OEM or tender setback would halve export growth.
Secular headwinds in auto segment (lower margin) and inventory destocking
MEDIUMAuto segment (mobile non-rail, 21% of Q2) is lower-margin and faces EV transition headwinds. No inventory build/destocking commentary on the call; working capital risk if orders soften.
The debate
What to watch next
1 · Rail plant trial runs (Nov–Dec 2026) and tender conversion
Do trial runs proceed on schedule and convert to orders by Q3? If yes, rail revenue should jump to 18–20% of Q3 and lift segment margins. If delayed or orders miss, the bear case hardens.
2 · Bharuch reaches 70% utilization target by Dec 2026
Is the ramp (₹75 Cr Q2 → target ₹100+ Cr by Q3) real or slipping further? If 70% is hit on schedule, ROE on the ₹70 Cr capex is on track. If slipped, capex payoff extends and execution risk escalates.
3 · QoQ operating profit stabilization or recovery in Q3 FY27
If cost pass-through works, OPM should hold or expand despite continued input inflation. If QoQ OPM declines further (or PAT remains flat/negative), pricing power is unproven and margin compression is structural, not transient. This is the number that resolves the bull–bear debate.
Timken delivered a headline-grabbing quarter on YoY metrics, but the sequential profit decline amid rising costs signals that the cycle is already slowing. This is not a step-change or recovery. It is a steady industrial business facing near-term margin headwinds and execution risk on a large capex ramp. The FII exit at 212 basis points is the street's vote: growth is real, but pricing power is unproven.
The stock has fallen 37% from its all-time high and sits below key moving averages. It is not yet cheap—not until the margin story stabilizes. The number to track from here is QoQ operating profit in Q3 FY27 (due by Dec 2026). If it holds or expands despite input costs, the bull case re-entry point emerges. If it compresses further, margin cycle deepens and the 37% drawdown may be just the opening act of a longer unwind. Until pricing power is proven, the risk/reward favors the sidelines.
Strong YoY growth, cost inflation offset by pricing power; Bharuch ramp tracking
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
Q2 FY27 revenue and PAT matched stated figures exactly. Capex guidance maintained; Bharuch target slipped from Aug-Sep to year-end, citing customer MOC delays.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Timken delivered 25.4% YoY revenue growth and 29.7% PAT growth, corroborating management's bullish narrative. However, QoQ growth was softer (revenue +2.8%, PAT -3.0%), and cost inflation is a rising structural headwind. Capex guidance reaffirmed but Bharuch utilization trails target at 60% vs. 70%. Export momentum and industrial segment accretion are genuine, but pricing power against input costs remains unproven.
₹969.3 Cr
Revenue · +25.4% YoY₹116.1 Cr
Reported PAT · +29.7% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
strong double-digit revenue growth, growth in profitability
METRevenue 969.3 Cr (+25.4% YoY), PAT 116.1 Cr (+29.7% YoY), OPM 18.4%, NPM 11.9%
4.3% growth over Q1 FY27
OVERSTATEDQoQ revenue growth was 2.8%; PAT declined 3.0% QoQ
Bharuch targeting 70% spherical roller bearing utilization by Aug-Sep
MixedBharuch at 60% SRB utilization as of Q2 call; target deferred to year-end
Exports grew 60% YoY and 30% QoQ
METQ2 exports revenue INR262.7 Cr (27% of total), strong growth trajectory confirmed in Q&A
Rail tenders delayed but moving; 3 weeks of tenders to materialize into orders
PartialRail revenue only INR156.7 Cr (16% of Q2, down-mix). Trial runs Nov-Dec, PPAPs after.
Earnings quality
What changed since the last call
Bharuch utilization timeline slipped
DowngradeQ1 guidance: 70% by Aug-Sep. Q2 call: 60% utilization, target deferred to year-end. Cited customer MOC/certification delays, not plant inefficiency.
Rail segment weakness highlighted
DowngradeMD: 'rail was low in the quarter. That is the unfavorable mix.' Global rail tender delayed; recovery in Q3-Q4 only. Rail was 16% of Q2 revenue.
Cost inflation as primary near-term risk
NewQ1 did not emphasize cost headwinds explicitly. Q2 call: 'cost going up and will still go up'; 'cost is going to be a challenge in coming months and years.' Magnitude of margin compression uncertain.
Capex guidance reaffirmed
NeutralFY27 capex at 8-10% of revenue unchanged. New Bharuch capex INR70 Cr disclosed (FRC + metal polymer). No upgrade to growth targets.
Exports & industrial segment performing
UpgradeExports grew 60% YoY, 30% QoQ (INR262.7 Cr, 27% of revenue). Industrial bearings (SRB, CRB) margin-accretive. Not previously flagged as a stand-out momentum driver.
The Q&A
Analysts pressed on rail delays, cost inflation, Bharuch utilization, and pricing power. Sanjay Koul answered directly with numbers (60% Bharuch, 16% rail mix), timelines (Nov-Dec trial runs), and candid cost narrative ('industry cannot absorb it'). No evasion; tone remained confident even when defending soft QoQ numbers.
Bharuch utilization, rail expansion — Raghunandhan NL, Nuvama Research
AnsweredSRB at 70%, CRB still below 60%. Bharuch Q2 revenue close to INR75 Cr. Utilization depends on customer MOCs; sales-side dependent. Still progressing.
Cost inflation impact, margin pass-through — Raghunandhan NL, Nuvama Research
PartialCost is rising and will continue to. Industry cannot absorb it; must pass on. But timing and degree of absorption by industry unknown. Working on it continuously.
Depreciation, Bharuch capex, margins by plant — Varun Jain, Dolat Capital
AnsweredDepreciation is reclassification between expenses, no structural reduction. Bharuch Q2 revenue INR75 Cr. SRB and CRB go to industrial segment, higher margin than automotive.
Rail expansion timeline, PPAPs — Varun Jain, Dolat Capital
PartialTrial runs Nov-Dec only; PPAPs after. Tenders were delayed; now moving. 3 weeks of tenders to materialize into orders. All on track.
SRB/CRB mix, year-end utilization targets — Rishi Vora, Kotak Securities
AnsweredCurrently heavily towards exports. CRBs 50-60%, SRB 70%. Overall year-end: 70-75% across units. Dependent on sales/customer side.
Global demand, India cost competitiveness — Ashish, Leo Capital
AnsweredDomestically, demand robust (GDP 7%, infrastructure in swing). US/Americas improving. India is in a good spot on cost, quality, delivery combined; not just cost.
Wind business, capacity expansion timeline — Rakesh, Axis AMC
AnsweredDomestic wind was sluggish, now picking up. Chinese/others moving production to India. We are in a nice spot. Capacity expansion maybe 3 years out. Market relevant for years.
Wind turbine upsizing, bearing substitution, GGB orders — Nikhil, iThoughtPMS
PartialTurbine sizes increasing (5+ MW common). Plain bearings may replace taper in some stages. GGB has won orders, supplying via brand. Not yet capitalized here; machines on-site, in commissioning. Will produce here soon.
Gearbox bearings, localization, market outlook — Nikhil, iThoughtPMS
AnsweredTimken India not localizing wind bearings. Parent Timken localizing elsewhere. We buy from sister concerns. Gearbox is low-margin; we serve it. Main shaft is profit driver, not gearbox.
Guidance
FY27 capex at 8-10% of revenue (reaffirmed)
HighPrior guidance from Q1 reaffirmed without change. Implies FY27 capex INR78-98 Cr at expected revenue run-rate.
Exports momentum to continue; North American rail tenders converting
MediumExports +60% YoY; management confident on North American rail alignment. Rail tenders in flight; PPAPs Nov-Dec onwards.
Bharuch to reach 70% utilization by year-end; plain bearing expansion on schedule
MediumCurrently 60% SRB, <60% CRB. Jamshedpur rail expansion and plain bearings capacity 'on schedule' but no numeric deliverables for FY27.
No explicit FY27 margin target restated
LowQ2 OPM 18.4%, NPM 11.9% delivered. No forward margin target disclosed. Cost inflation acknowledged as headwind.
Industrial segment (SRB/CRB) margin-accretive; price increases to pass on costs
MediumMD: industrial always better margin than auto. Passing on cost inflation; degree/timing of absorption unproven. QoQ PAT -3% suggests absorption ongoing.
Bharuch: INR70 Cr for FRC & metal polymer (approved, undergoing)
HighCFO: 'Think very close to they're into INR70 crores, INR75 crores.' Asset turn expected 1 to 1.5x.
Rail plant expansion: INR120 Cr, trial runs Nov-Dec, PPAPs after
HighTrial runs starting in Nov-Dec; commercialization Q3-Q4 FY27. Tenders in flight, some interim orders on wagon builders.
GGB investment: INR35-70 Cr (ramp-up of sister concern's wind bearing production)
MediumGGB to produce plain bearings for wind gearboxes. Machines on-site; commissioning in progress. Orders won but not yet capitalized.
Risks the call surfaced
Cost inflation & margin pressure
HighInput costs (carbides, steel, gas) rising materially. Industry cannot absorb; must pass to customers. QoQ PAT -3% despite +2.8% revenue growth suggests partial absorption. Pricing power against OEM customers uncertain.
Rail segment weakness & tenders
MediumRail segment only 16% of Q2 revenue, weighed by global tender delays. Recovery hinges on Nov-Dec trial runs and tender conversion. Delayed PPAPs and regulatory process may slip commercialization.
Bharuch plant utilization shortfall
MediumBharuch at 60% SRB utilization Q2; prior target was 70% by Aug-Sep. Deferred to year-end. MOC/certification delays on customer side. Risk of further delays or lower-than-expected steady-state utilization.
Capex execution & funding
MediumLarge capex program: Bharuch INR70 Cr, rail INR120 Cr, GGB INR35-70 Cr. Total ~INR225+ Cr over next 2 years. Asset turn expectations (Bharuch 1-1.5x) untested. Execution risk on all three fronts.
Export concentration & customer dependence
MediumExports 27% of Q2 revenue, growing 60% YoY. Heavy exposure to North American rail and process industries (gearbox makers). No quantified customer concentration disclosed, but references to 'ZFs and Flenders' and North American rail suggest concentrated customer base.
Management
Score 7/10. Clear, specific, candid. Sanjay Koul provided revenue breakdowns (5 segments), utilization levels (60%, 70%), and timelines (Nov-Dec). Openly admitted cost inflation risk and Bharuch target slip. No defensive jargon; acknowledged limits ('I didn't understand the question'). Mixed. Delivered Q2 revenue and PAT matched claims (+25.4% YoY, +29.7% YoY). Rail expansion slipped from Aug-Sep to Nov-Dec trial runs. Bharuch at 60% vs. 70% target. Capex programs on track but timelines extending.
1 · Nov-Dec 2026
Rail plant trial runs begin; PPAPs and tenders convert to orders
2 · Q3 FY27 (by Dec 2026)
Bharuch SRB utilization reaches 70% target; Jamshedpur plain bearings capacity live
3 · Q4 FY27 (by Mar 2027)
Wind business ramp; GGB order wins materialize on Bharuch; annual utilization targets achieved
Export momentum and industrial segment accretion are genuine, but pricing power against input costs remains unproven.
Timken Q2 FY27 — margin gradient at reset; watch exports & plant ramp
After a solid Q1 (18.5% EBITDA margins, 14.9% revenue growth), Timken faces a softer demand backdrop but has structural momentum from export growth and new capacity coming. Q2 will test whether the margin floor holds and if wind/process segments offset auto/rail weakness.
The quarter at a glance
Timken India reports Q2 FY27 (Sept 2026) on 29 October 2026. The company enters this quarter on the back of a solid Q1 — revenue ₹929 Cr (+14.9% YoY), EBITDA margins at 18.5% (+93 bps YoY) — and on the back of a structural shift: strong export growth (up 21% YoY), wind energy and process segments driving demand, and new capacity coming onstream over FY27–28. The near-term ask is margin consistency. With demand soft in auto and railways, Q2 will test whether the wind/export momentum and higher-margin product mix are enough to hold the 18%+ EBITDA floor.
~₹935–950 Cr
Q1 ₹929 Cr at +14.9% YoY; full-year guide ₹15.3% growth implies Q2 seasonal ramp typical of industrial cycle.
18.0–19.0%
Q1 at 18.5%. Analyst consensus forecasts 19–21% by FY28; margin trajectory is the real debate.
~₹115–125 Cr
Q1 ₹115 Cr. FY27 profit growth guide 28.2%; sequential growth depends on mix and operating leverage.
Track 20%+ YoY
Q1 exports +21% YoY despite geopolitical drag. Q2 confirmation of run-rate = validation of global demand thesis.
A strong Q2 would show: revenue growth holding 14–15% YoY, EBITDA margin at 18.5%+, export growth sustained at 20%+, and management commentary confirming medium-term guidance intact (FY28 EBITDA margin 19–21%). A weak Q2 would flag: revenue growth slipping below 10%, EBITDA margin falling back to 17–17.5%, exports normalizing due to macro headwind, or management pulling back FY28 margin guidance due to near-term demand deterioration.
On-plan? The Street view
The company is tracking full-year guidance. Q1 revenue growth of 14.9% sits comfortably within the 15.3% FY27 guide. Margin trajectory (Q1 at 18.5%, target 19–21% by FY28) implies a ramp through FY27–28; Q2 will signal whether Q1 was a one-off or the start of a trend. Management expects medium-term support from government capex, PLI incentives, and new capacity. Near-term visibility remains lumpy — auto and railways (historically ~30–40% of revenue mix) are soft — but process and wind segments are picking up.
What's changed since Q1
1 · Management change — Pramesh Maheshwari as President (Oct 12, 2026)
Timken India appointed Pramesh Maheshwari (30+ years in EBITDA growth, operations) as President — India & Southeast Asia. New leader's mandate likely includes new plant ramp and cost/margin optimization. Watch for strategic priorities on Q2 call.
2 · AGM dividend (Aug 18, 2026) — ₹2.50 per share approved
Routine dividend approval at 39th AGM for FY26. At ₹2.50 on a ₹2,748 stock, yield ~0.9%. No change in capital allocation signal.
3 · BIS licenses for bearings (Jul 13, 2026) — four new certifications
Timken secured BIS approval for CRB and TRB production at multiple plants. Regulatory approvals for domestic bearing standards — necessary for OEM and domestic infrastructure deals. Positive but routine.
4 · Merger scheme accepted (Jul 24, 2026) — NCLT first motion for Timken GGB amalgamation
National Company Law Tribunal approved first motion for merging Timken GGB (wholly-owned subsidiary) into Timken India. Simplifies structure; not immediately accretive but clears a corporate housekeeping item.
Three things to watch on result day
1 · Revenue mix & export run-rate
Q1 exports +21% YoY — is this sustained or a timing blip? Wind/process segment growth (Q1 strength) — magnitude and margin profile. If export growth slips below 15% or wind growth moderates, signal is caution on FY27 momentum.
2 · EBITDA margin — does it stick at 18%+?
Q1 at 18.5% was above prior run-rate (18% implied in FY26). If Q2 margin is 17.5%–18.0%, signals near-term headwind or product mix pressure. If 18.5%+, analyst thesis of 19–21% FY28 starts credible.
3 · FY27–28 guidance reaffirmation + plant ramp timetable
Management guide FY27 revenue +15.3%, profit +28.2%, and EBITDA margin expansion to 19–21% by FY28. Watch for: (a) reiteration, (b) any pull-back due to auto/rail softness, (c) detail on Bharuch & Jamshedpur commercial production dates and capacity assumptions.
Timken India enters Q2 FY27 with structural tailwinds (exports +21%, wind/process growth, new capacity) but near-term headwind (auto/railway demand soft). Q1 was solid — 14.9% revenue growth, 18.5% EBITDA margin — and the Street expects full-year guidance (FY27 +15.3% revenue, +28.2% profit, margin expansion to 19–21%) to hold. The real test is margin consistency: if Q2 sustains 18%+ EBITDA and exports remain 20%+ YoY, analyst consensus of 26–32% upside (₹3,988–4,560 target) becomes plausible. Conversely, if auto/rail weakness bleeds into margins or export growth normalizes, Street expectations may need reset. Watch the margin gradient and new-plant commentary most closely.